BACKGROUND: Many genetic studies on gliomas have reported the utility of DNA copy number aberrations (CNAs) in tumor classification, and we have previously shown that grade II -III adult supratentorial gliomas could be classified into clinically relevant subgroups based on the CNAs. The major CNAs in astrocytic tumors of these grades were gain of whole chromosome 7 (+7) and that on chromosomal arm 7q (+7q), and tumors with +7 had a worse outcome than tumors with 7q. However, it was not confirmed that the former could develop from the latter; that is, it is not clear that a stepwise DNA copy number gain on chromosome 7, beginning as partial gain of 7q, develops along with glioma progression. We then aimed to establish glioma development pathway model by combining information on CNAs and other
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